DDInter893 DDInter1376
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Chloroquine
Hydroxychloroquine {u} (Compound) resembles {v} (Compound) Amodiaquine
Hydroxychloroquine {u} may lead to a major life threatening interaction when taken with {v} Primaquine
Hydroxychloroquine {u} (Compound) binds {v} (Gene) TLR9
Hydroxychloroquine {u} (Compound) upregulates {v} (Gene) PAK1
Hydroxychloroquine {u} (Compound) downregulates {v} (Gene) TES
Hydroxychloroquine {u} (Compound) causes {v} (Side Effect) Vomiting
Hydroxychloroquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Hydroxychloroquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Hydroxychloroquine (Compound) resembles Chloroquine (Compound)
Hydroxychloroquine (Compound) resembles Amodiaquine (Compound)
Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Hydroxychloroquine (Compound) binds TLR9 (Gene)
Hydroxychloroquine (Compound) upregulates PAK1 (Gene)
Hydroxychloroquine (Compound) downregulates TES (Gene)
Hydroxychloroquine (Compound) causes Vomiting (Side Effect)
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131